HRP20210399T1 - Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) - Google Patents
Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) Download PDFInfo
- Publication number
- HRP20210399T1 HRP20210399T1 HRP20210399TT HRP20210399T HRP20210399T1 HR P20210399 T1 HRP20210399 T1 HR P20210399T1 HR P20210399T T HRP20210399T T HR P20210399TT HR P20210399 T HRP20210399 T HR P20210399T HR P20210399 T1 HRP20210399 T1 HR P20210399T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- antigen
- binding portion
- use according
- hpv
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 5
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 title claims 4
- 238000000034 method Methods 0.000 title claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 title 1
- 108010074708 B7-H1 Antigen Proteins 0.000 title 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 241000701806 Human papillomavirus Species 0.000 claims 8
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 102000006311 Cyclin D1 Human genes 0.000 claims 1
- 108010058546 Cyclin D1 Proteins 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000012303 cytoplasmic staining Methods 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 238000012758 nuclear staining Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 238000011518 platinum-based chemotherapy Methods 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
Claims (17)
1. Antitijelo ili njegov dio koji se vezuje za antigen, koji se specifično vezuje za receptor programirane smrti-1 (PD-1) ili ligand programirane smrti-1 (PD-L1) i inhibira PD-1 aktivnost za primjenu u postupku liječenja subjekta koji je pogođen tumorom izvedenim iz raka glave i vrata karcinoma skvamoznih stanica (SCCHN) pozitivnog na humani papiloma virus (HPV) koji obuhvaća administriranje subjektu terapijski efikasne količine antitijela ili njegovog dijela koji veže antigen, pri čemu je subjekt identificiran kao HPV pozitivan.
2. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 1, pri čemu HPV-pozitivni SCCHN obuhvaća tumor koji eksprimira jedan ili više proteina izvedenih iz HPV ili obuhvaća nukleotidnu sekvencu koja kodira jedan ili više proteina.
3. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 2, pri čemu jedan ili više proteina izvedenih iz HPV obuhvaćaju p16, Ki-67, ciklin D1, p53, ProEx C, E6, E7, ili bilo koju njihovu kombinaciju.
4. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu HPV obuhvaća HPV podtip 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, ili bilo koju njihovu kombinaciju.
5. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu više od oko 70% tumorskih stanica pokazuje snažno i difuzno nuklearno i citoplazmatsko bojenje imunohistokemijom protiv p16.
6. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu tumor dalje eksprimira PD-L1.
7. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 6, pri čemu antitijelo je kimerno, humanizirano ili humano monoklonsko antitijelo ili njegov dio.
8. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu antitijelo obuhvaća konstantnu regiju teškog lanca koji je od humanog IgG1 ili IgG4 izotipa.
9. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 8, pri čemu antitijelo je nivolumab ili pembrolizumab.
10. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 9, pri čemu antitijelo se administrira u dozi od najmanje oko 3 mg/kg tjelesne težine ili 240 mg jednom na svaka 2 tjedna.
11. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 8, pri čemu antitijelo specifično vezuje PD-L1.
12. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 11, pri čemu antitijelo je odabrano iz grupe koja se sastoji od MPDL3280A, durvalumaba, i avelumaba.
13. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 12, pri čemu postupak dalje obuhvaća administriranje jednog ili više dodatnih agenasa protiv raka.
14. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 13, pri čemu agens protiv raka je odabran iz grupe koja se sastoji od antitijela ili njegovog dijela koji se vezuje za antigen, koji se specifično vezuje za CTLA-4 i inhibira CTLA-4 aktivnost, kemoterapije, dvostruke kemoterapije na bazi platine, inhibitora tirozin kinaze, anti-VEGF inhibitora, ili bilo koje njihove kombinacije.
15. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 14, pri čemu subjekt je primio jedan ili više agenasa protiv raka prije administriranja antitijela.
16. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 15, pri čemu jedan ili više agenasa protiv raka nisu bili efikasni u liječenju tumora.
17. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 16, pri čemu jedan ili više agenasa protiv raka obuhvaćaju terapiju na bazi platine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562192396P | 2015-07-14 | 2015-07-14 | |
EP16744626.9A EP3322731B1 (en) | 2015-07-14 | 2016-07-14 | Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1) |
PCT/US2016/042297 WO2017011666A1 (en) | 2015-07-14 | 2016-07-14 | Method of treating cancer using immune checkpoint inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210399T1 true HRP20210399T1 (hr) | 2021-04-30 |
Family
ID=56551000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210399TT HRP20210399T1 (hr) | 2015-07-14 | 2021-03-08 | Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) |
Country Status (16)
Country | Link |
---|---|
US (3) | US10544224B2 (hr) |
EP (2) | EP3858859A1 (hr) |
JP (2) | JP2018522887A (hr) |
KR (1) | KR20180027576A (hr) |
CN (1) | CN107922502A (hr) |
CY (1) | CY1123993T1 (hr) |
DK (1) | DK3322731T3 (hr) |
ES (1) | ES2855798T3 (hr) |
HR (1) | HRP20210399T1 (hr) |
HU (1) | HUE053966T2 (hr) |
LT (1) | LT3322731T (hr) |
PL (1) | PL3322731T3 (hr) |
PT (1) | PT3322731T (hr) |
RS (1) | RS61532B1 (hr) |
SI (1) | SI3322731T1 (hr) |
WO (1) | WO2017011666A1 (hr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
ES2803655T3 (es) | 2015-05-29 | 2021-01-28 | Agenus Inc | Aticuerpos anti-ctla-4 y métodos de uso de los mismos |
EP3313186A4 (en) | 2015-06-29 | 2019-04-03 | Biomed Valley Discoveries, Inc. | COMBINATION OF LPT-723 INHIBITORS AND IMMUNE CONTROL POINT AND METHODS OF TREATMENT |
KR20180040138A (ko) | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법 |
EP3858859A1 (en) | 2015-07-14 | 2021-08-04 | Bristol-Myers Squibb Company | Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1) |
EP3334763B1 (en) | 2015-08-11 | 2024-08-07 | WuXi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
CN107949573B (zh) | 2015-09-01 | 2022-05-03 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
TWI795347B (zh) * | 2015-11-18 | 2023-03-11 | 美商必治妥施貴寶公司 | 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌 |
US20200261573A1 (en) * | 2015-12-17 | 2020-08-20 | Novartis Ag | Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof |
WO2017157882A1 (en) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Serine biosynthetic pathway inhibitors |
EP3522923A1 (en) * | 2016-10-06 | 2019-08-14 | Pfizer Inc | Dosing regimen of avelumab for the treatment of cancer |
ES2963226T3 (es) | 2016-12-07 | 2024-03-26 | Agenus Inc | Anticuerpos ANTI-CTLA-4 y métodos de uso de los mismos |
CN110300599B (zh) | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | 抗体和其使用方法 |
NZ759442A (en) | 2017-06-01 | 2024-07-05 | Cytomx Therapeutics Inc | Activatable anti-pdl1 antibodies, and methods of use thereof |
WO2018226529A1 (en) * | 2017-06-05 | 2018-12-13 | The Regents Of The University Of Michigan | Complexes for delivery of antigenic peptides |
KR20200129092A (ko) * | 2018-01-12 | 2020-11-17 | 그레일, 인코포레이티드. | 바이러스 핵산을 분석하기 위한 방법 |
US20210047409A1 (en) * | 2018-02-13 | 2021-02-18 | Merck Sharp & Dohme Corp. | Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies |
WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
KR20200139724A (ko) * | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
EP3801501A4 (en) * | 2018-06-06 | 2022-03-23 | The Regents of the University of California | ESTROGEN RECEPTOR INHIBITORS AND THEIR USES |
US20210255168A1 (en) * | 2018-06-13 | 2021-08-19 | King Faisal Specialist Hospital & Research Centre | A method of precision cancer therapy |
JP2022509448A (ja) * | 2018-10-31 | 2022-01-20 | ジェネンテック, インコーポレイテッド | Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 |
WO2020156500A1 (zh) * | 2019-01-31 | 2020-08-06 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
KR20220115803A (ko) * | 2019-12-13 | 2022-08-18 | 삼성바이오에피스 주식회사 | 안정한 항-pd-1 항체 약제학적 제제 |
WO2021126906A1 (en) * | 2019-12-20 | 2021-06-24 | Merck Sharp & Dohme Corp. | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
KR102541413B1 (ko) | 2020-02-06 | 2023-06-12 | 영남대학교 산학협력단 | 면역 체크포인트 억제제 및 ampk 활성화제를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물 |
KR20240013352A (ko) | 2022-07-22 | 2024-01-30 | 가톨릭대학교 산학협력단 | 디옥시시코닌 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
IL144578A0 (en) | 1999-01-29 | 2002-05-23 | Imclone Systems Inc | Antibodies specific to kdr and uses thereof |
DK1210428T3 (en) | 1999-08-23 | 2015-06-15 | Dana Farber Cancer Inst Inc | PD-1, a receptor for B7-4 AND USE THEREOF |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
ES2347543T3 (es) | 2002-03-04 | 2010-11-02 | Imclone Llc | Anticuerpos humanos especificos para kdr y sus usos. |
EP3287144A1 (en) | 2002-07-03 | 2018-02-28 | ONO Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
ES2523457T3 (es) | 2004-11-18 | 2014-11-26 | Imclone Llc | Anticuerpos contra el receptor 1 del factor de crecimiento endotelial vascular |
KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
EP2397155B1 (en) * | 2005-06-08 | 2017-12-13 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway |
DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
BRPI0812913B8 (pt) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
EA034136B1 (ru) | 2007-11-09 | 2020-01-09 | Перигрин Фармасьютикалз, Инк. | Изолированное антитело, которое связывается с vegf, и его применения |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
HUE049647T2 (hu) | 2009-11-24 | 2020-09-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
ES2699965T3 (es) | 2011-03-10 | 2019-02-13 | Provectus Pharmatech Inc | Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer |
RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
SG11201402603WA (en) | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
BR112014028826B1 (pt) | 2012-05-15 | 2024-04-30 | Bristol-Myers Squibb Company | Uso de nivolumab ou pembrolizumabe |
BR112015007184A2 (pt) | 2012-10-02 | 2017-08-08 | Bristol Myers Squibb Co | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer |
ES2927567T3 (es) | 2013-09-13 | 2022-11-08 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
HRP20230603T1 (hr) * | 2013-09-20 | 2023-09-29 | Bristol-Myers Squibb Company | Kombinacija anti-lag-3 antitijela i anti-pd-1 antitijela za liječenje tumora |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
KR20170007750A (ko) | 2014-05-29 | 2017-01-20 | 메디뮨 리미티드 | Hpv-음성 암의 치료를 위한 pdl-1의 길항제 및 pd-1의 길항제 |
US10354541B2 (en) | 2014-07-02 | 2019-07-16 | Raytheon Bbn Technologies Corporation | Tutor model building system |
MA40344A (fr) * | 2014-07-18 | 2016-01-21 | Advaxis Inc | Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer |
WO2016029073A2 (en) * | 2014-08-22 | 2016-02-25 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
BR112017021688A2 (pt) * | 2015-04-17 | 2018-08-14 | Bristol-Myers Squibb Company | composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo |
EP3858859A1 (en) | 2015-07-14 | 2021-08-04 | Bristol-Myers Squibb Company | Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1) |
-
2016
- 2016-07-14 EP EP20214749.2A patent/EP3858859A1/en active Pending
- 2016-07-14 KR KR1020187003984A patent/KR20180027576A/ko not_active Application Discontinuation
- 2016-07-14 EP EP16744626.9A patent/EP3322731B1/en active Active
- 2016-07-14 PL PL16744626T patent/PL3322731T3/pl unknown
- 2016-07-14 SI SI201631090T patent/SI3322731T1/sl unknown
- 2016-07-14 CN CN201680052756.8A patent/CN107922502A/zh active Pending
- 2016-07-14 PT PT167446269T patent/PT3322731T/pt unknown
- 2016-07-14 HU HUE16744626A patent/HUE053966T2/hu unknown
- 2016-07-14 DK DK16744626.9T patent/DK3322731T3/da active
- 2016-07-14 ES ES16744626T patent/ES2855798T3/es active Active
- 2016-07-14 RS RS20210284A patent/RS61532B1/sr unknown
- 2016-07-14 US US15/210,612 patent/US10544224B2/en active Active
- 2016-07-14 WO PCT/US2016/042297 patent/WO2017011666A1/en active Application Filing
- 2016-07-14 JP JP2018501155A patent/JP2018522887A/ja active Pending
- 2016-07-14 LT LTEP16744626.9T patent/LT3322731T/lt unknown
-
2019
- 2019-12-05 US US16/704,913 patent/US20200190198A1/en not_active Abandoned
-
2021
- 2021-03-08 HR HRP20210399TT patent/HRP20210399T1/hr unknown
- 2021-03-26 CY CY20211100264T patent/CY1123993T1/el unknown
-
2022
- 2022-10-21 JP JP2022169277A patent/JP2023024973A/ja active Pending
-
2023
- 2023-07-26 US US18/359,696 patent/US20240124592A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20180027576A (ko) | 2018-03-14 |
EP3322731B1 (en) | 2021-01-13 |
US20240124592A1 (en) | 2024-04-18 |
CY1123993T1 (el) | 2022-05-27 |
LT3322731T (lt) | 2021-03-25 |
RS61532B1 (sr) | 2021-04-29 |
EP3322731A1 (en) | 2018-05-23 |
JP2018522887A (ja) | 2018-08-16 |
DK3322731T3 (da) | 2021-03-08 |
PT3322731T (pt) | 2021-02-25 |
ES2855798T3 (es) | 2021-09-24 |
EP3858859A1 (en) | 2021-08-04 |
US20170037132A1 (en) | 2017-02-09 |
US10544224B2 (en) | 2020-01-28 |
US20200190198A1 (en) | 2020-06-18 |
HUE053966T2 (hu) | 2021-08-30 |
JP2023024973A (ja) | 2023-02-21 |
WO2017011666A1 (en) | 2017-01-19 |
SI3322731T1 (sl) | 2021-03-31 |
PL3322731T3 (pl) | 2021-05-31 |
CN107922502A (zh) | 2018-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210399T1 (hr) | Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) | |
JP2018522887A5 (hr) | ||
HRP20210440T1 (hr) | Kombinirana terapija za rak | |
HRP20231156T1 (hr) | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka | |
KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-b7-h1 및 항-ctla-4 항체 | |
HRP20192285T1 (hr) | Anti-ox40 protutijela i postupci uporabe | |
RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
RU2017117664A (ru) | Комбинация | |
EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
JP2017537090A5 (hr) | ||
MY196756A (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
US11230598B2 (en) | Antibodies and methods for depleting regulatory bio cells and use in combination with immune checkpoint inhibitors | |
MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
IL278423B2 (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
JP2018500332A5 (hr) | ||
PH12018500174A1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
RU2017105118A (ru) | Нейтрализация ингибирующих путей в лимфоцитах | |
EP3572430A3 (en) | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent | |
MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
MA44560B1 (fr) | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains | |
JP2019503387A5 (hr) |